Uncover Therapeutics
Uncover Therapeutics is developing a potential first-in-class cancer immunotherapy that combines checkpoint inhibition with targeted immune activation to overcome resistance in solid tumors. The therapy is designed to convert the tumor's immune-suppressive shield into an immune-stimulatory signal, with the lead asset approximately 12-15 months from regulatory submission for first-in-human trials.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
While immunotherapy has transformed outcomes for some cancer patients, the majority still do not benefit, representing one of the largest unmet needs in oncology. Current immune-oncology therapies are limited in their ability to overcome the immune-suppressive mechanisms that solid tumors use to evade detection and attack.
Solution
Uncover Therapeutics is advancing a potential first-in-class therapy designed to overcome the key limitations of current immune-oncology approaches. The therapy combines checkpoint inhibition with targeted immune activation, engineered to transform cancer's immune shield into an immune beacon that reactivates and expands the immune response. Supported by compelling preclinical data, the lead asset is approximately 12-15 months from regulatory submission to enable first-in-human clinical trials in solid tumors. The approach aims to unlock deeper and more durable anti-tumour responses than existing immunotherapies, harnessing the tumour microenvironment to amplify anti-tumour immunity.
Target Audience
Primary stakeholders are oncology researchers, clinical development teams, and potential pharmaceutical partners focused on advancing novel immunotherapies for solid tumor indications.
Features
- First-in-class mechanism combining checkpoint inhibition with targeted immune activation
- Designed to convert tumor immune evasion into an immune-stimulatory signal
- Harnesses the tumour microenvironment to amplify anti-tumour immunity
- Compelling preclinical data supporting advancement toward clinical development
- Lead asset positioned for regulatory submission within 12-15 months
- Focus on solid tumors, addressing a significant unmet medical need